Construction of "Coral" SERS sensor for ultrasensitive and rapid detection of harmful component macrophage migration inhibitory factor in Platelet-rich Plasma.

Macrophage migration inhibitory factor Osteoarthritis Platelet-rich plasma therapy Point-of-Care testing Surface-enhanced Raman spectroscopy

Journal

Biosensors & bioelectronics
ISSN: 1873-4235
Titre abrégé: Biosens Bioelectron
Pays: England
ID NLM: 9001289

Informations de publication

Date de publication:
15 Dec 2023
Historique:
received: 06 09 2023
accepted: 28 09 2023
medline: 30 10 2023
pubmed: 7 10 2023
entrez: 6 10 2023
Statut: ppublish

Résumé

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory factor produced by residual red blood cell lysis, which can significantly influence the curative effect of Platelet-rich plasma (PRP) therapy used for osteoarthritis (OA) treatment. In this study, we proposed a novel approach for detecting the concentration of MIF in PRP using a dopamine-coated antibody-Au (core)-Ag (shell)-SERS sensor, which enables ultrasensitive and rapid detection of MIF. The best experimental conditions have a detection limit of only 90.05 pg/mL and a good linear relationship between 1-5000 ng/mL. In 40 PRP samples collected from actual clinical patients, we detected MIF concentrations ranging from 2.0-3.6 ng/mL. This indicated that the Coral SERS sensor not only allows for results highly consistent with the traditional ELISA method, but also costs less ($0.40-$0.70), needs shorter testing time (integration time is only 10s), and consumes less PRP that can greatly improve the sample quality and maximize the curative effect in clinical applications for OA treatment with PRP.

Identifiants

pubmed: 37801837
pii: S0956-5663(23)00660-7
doi: 10.1016/j.bios.2023.115718
pii:
doi:

Substances chimiques

Macrophage Migration-Inhibitory Factors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115718

Informations de copyright

Copyright © 2023 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yiran Zhu (Y)

Department of Orthopedics, Sir Run Run Hospital, Nanjing Medical University, Nanjing, PR China.

Yang Sun (Y)

Department of Forensic Medicine, Nanjing Medical University, Nanjing, PR China.

Yang Shi (Y)

School of Pharmacy, Nanjing Medical University, Nanjing, PR China.

Yan Ding (Y)

Department of Forensic Medicine, Nanjing Medical University, Nanjing, PR China.

Cheng Liu (C)

Department of Forensic Medicine, Nanjing Medical University, Nanjing, PR China.

Fei Yang (F)

Department of Orthopedics, Sir Run Run Hospital, Nanjing Medical University, Nanjing, PR China.

Feng Chen (F)

Department of Forensic Medicine, Nanjing Medical University, Nanjing, PR China. Electronic address: fchen@njmu.edu.cn.

Yue Cao (Y)

Department of Forensic Medicine, Nanjing Medical University, Nanjing, PR China. Electronic address: ycao@njmu.edu.cn.

Jian Qin (J)

Department of Orthopedics, Sir Run Run Hospital, Nanjing Medical University, Nanjing, PR China. Electronic address: qinjian@njmu.edu.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH